FibroBiologics, Inc. (FBLG)Healthcare | Biotechnology | Houston, United States | NasdaqCM
1.53 USD
+0.01
(0.658%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.50 -0.03 (-0.030%) ⇩ (April 17, 2026, 7:51 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 1:32 p.m. EDT
FBLG is currently trading at a significant discount, with a current price of $1.35, which is well below its 52-week low of $1.03. The stock has experienced a sharp decline over the past few weeks, with a 50-day average of $5.17 and a 200-day average of $8.28, indicating a strong downward trend. The stock's beta of 1.105 suggests it is slightly more volatile than the market. The negative forward PE and trailing EPS indicate poor earnings performance, and the negative return on assets and equity further highlight financial distress. Recent news includes a reverse stock split and a public offering, which may signal financial difficulties. The lack of dividends and a history of negative cash flow make it unsuitable for dividend-focused investors. Given the poor fundamentals and significant price drop, it is not advisable to invest in FBLG for short-term or long-term gains. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.387891 |
| MSTL | 0.415807 |
| AutoARIMA | 0.421027 |
| AutoETS | 0.422611 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 21% |
| H-stat | 32.16 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.001 |
| Excess Kurtosis | 0.52 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 39.149 |
| Market Cap | 6,948,698 |
| Forward P/E | -0.40 |
| Beta | 1.11 |
| Website | https://fibrobiologics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9449275 |
| Address1 | 455 East Medical Center Boulevard |
| Address2 | Suite 300 |
| All Time High | 1,100.0 |
| All Time Low | 1.03 |
| Ask | 1.59 |
| Ask Size | 2 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 322,040 |
| Average Daily Volume3 Month | 325,106 |
| Average Volume | 325,106 |
| Average Volume10Days | 322,040 |
| Beta | 1.105 |
| Bid | 1.5 |
| Bid Size | 2 |
| Book Value | 1.851 |
| City | Houston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.53 |
| Current Ratio | 3.609 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.83 |
| Day Low | 1.45 |
| Debt To Equity | 39.149 |
| Display Name | FibroBiologics |
| Earnings Timestamp End | 1,755,201,600 |
| Earnings Timestamp Start | 1,755,201,600 |
| Ebitda | -16,405,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.164 |
| Enterprise Value | 2,686,996 |
| Eps Current Year | -3.705 |
| Eps Forward | -3.845 |
| Eps Trailing Twelve Months | -8.4 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.6786 |
| Fifty Day Average Change | -3.1485999 |
| Fifty Day Average Change Percent | -0.6729791 |
| Fifty Two Week Change Percent | -94.49275 |
| Fifty Two Week High | 30.6 |
| Fifty Two Week High Change | -29.07 |
| Fifty Two Week High Change Percent | -0.95 |
| Fifty Two Week Low | 1.03 |
| Fifty Two Week Low Change | 0.5 |
| Fifty Two Week Low Change Percent | 0.48543692 |
| Fifty Two Week Range | 1.03 - 30.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,706,711,400,000 |
| Float Shares | 2,930,738 |
| Forward Eps | -3.845 |
| Forward P E | -0.39791936 |
| Free Cashflow | -9,968,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 15 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.14468999 |
| Held Percent Institutions | 0.08519 |
| Implied Shares Outstanding | 4,541,633 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-01-31 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,774,828,800 |
| Last Split Factor | 1:20 |
| Long Business Summary | FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas. |
| Long Name | FibroBiologics, Inc. |
| Market | us_market |
| Market Cap | 6,948,698 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1758633149 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -18,646,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,828,345 |
| Number Of Analyst Opinions | 3 |
| Open | 1.55 |
| Operating Cashflow | -16,394,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 281 671 5150 |
| Post Market Change | -0.029999971 |
| Post Market Change Percent | -1.9607825 |
| Post Market Price | 1.5 |
| Post Market Time | 1,776,469,871 |
| Previous Close | 1.52 |
| Price Eps Current Year | -0.41295546 |
| Price Hint | 4 |
| Price To Book | 0.8265802 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.782 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | 0.00999999 |
| Regular Market Change Percent | 0.657894 |
| Regular Market Day High | 1.83 |
| Regular Market Day Low | 1.45 |
| Regular Market Day Range | 1.45 - 1.83 |
| Regular Market Open | 1.55 |
| Regular Market Previous Close | 1.52 |
| Regular Market Price | 1.53 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 704,339 |
| Return On Assets | -0.79847 |
| Return On Equity | -4.19435 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 4,541,633 |
| Shares Percent Shares Out | 0.059699997 |
| Shares Short | 209,586 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 33,563 |
| Short Name | FibroBiologics, Inc. |
| Short Percent Of Float | 0.0656 |
| Short Ratio | 0.43 |
| Source Interval | 15 |
| State | TX |
| Symbol | FBLG |
| Target High Price | 30.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 19.0 |
| Target Median Price | 19.0 |
| Total Cash | 4,894,000 |
| Total Cash Per Share | 1.448 |
| Total Debt | 2,410,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -8.4 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.97815 |
| Two Hundred Day Average Change | -6.4481497 |
| Two Hundred Day Average Change Percent | -0.80822617 |
| Type Disp | Equity |
| Volume | 704,339 |
| Website | https://fibrobiologics.com |
| Zip | 77,598 |